Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares hit a new 52-week low during mid-day trading on Thursday after SunTrust Banks lowered their price target on the stock to $12.00. SunTrust Banks currently has a buy rating on the stock. Conatus Pharmaceuticals traded as low as $1.80 and last traded at $2.16, with a volume of 131041 shares. The stock had previously closed at $4.50.

A number of other analysts have also recently weighed in on CNAT. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. HC Wainwright restated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, November 5th. Finally, Stifel Nicolaus cut shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $11.12.

Hedge funds have recently added to or reduced their stakes in the stock. Alambic Investment Management L.P. boosted its stake in Conatus Pharmaceuticals by 207.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 178,461 shares in the last quarter. Bank of America Corp DE boosted its stake in Conatus Pharmaceuticals by 75.7% in the 2nd quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 60,604 shares in the last quarter. Paloma Partners Management Co purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $547,000. Artal Group S.A. purchased a new position in Conatus Pharmaceuticals during the 3rd quarter worth approximately $2,900,000. Finally, MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $154,000. Institutional investors own 31.93% of the company’s stock.

The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 2.39. The stock has a market capitalization of $136.18 million, a PE ratio of -2.80 and a beta of 1.99.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $9.70 million. On average, analysts anticipate that Conatus Pharmaceuticals Inc will post -0.6 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Conatus Pharmaceuticals (CNAT) Hits New 1-Year Low After Analyst Downgrade” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/conatus-pharmaceuticals-cnat-hits-new-1-year-low-after-analyst-downgrade/2668973.html.

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.